Abstract
This study was conducted to investigate a method of gene therapy for proliferative vitreoretinopathy (PVR) by inhibiting type β transforming growth factor (TGF-β). PVR was induced in pigmented rabbits by intravitreal injection of 50 000 rabbit conjunctival fibroblasts after vitrectomy. Subsequently, the eyes received an intravitreal application of adenovirus vector encoding a soluble type II TGF-β receptor (AdTβ-ExR, n = 10) or adenoviral vector expressing β-galactosidase (AdLacZ) (n = 10) or balanced salt solution (BSS) (n = 6). The eyes were examined ophthalmoscopically for 28 days after surgery, and the clinical stage of PVR was evaluated on a scale of zero to five. Histological examinations were performed on the treated eyes on day 28. All control eyes injected with AdLacZ or BSS developed PVR, characterized by retinal detachment and the formation of intravitreal membranes within 7 days. The eyes injected with AdTβ-ExR also developed features of PVR, but the average severity from day 5 to day 28 was significant lower than in the control eyes (P < 0.05). TGF-β plays an important role in PVR progression in a PVR model, and prevention of TGF-β signaling could be therapeutically useful.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Retina Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy Ophthalmology 1983 90: 121–125
Glaser BM, Lemor M . Pathology of proliferative vitreoretinopathy Ryan SJ (eds); Retina CV Mosby 1994 pp 2249–2263
Wiedemann P . Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration Surv Ophthalmol 1992 36: 373–384
Kon CH, Occleston NL, Aylward GW, Khaw PT . Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study Invest Ophthalmol Vis Sci 1999 40: 705–712
Esser P et al. Apoptosis in proliferative vitreoretinal disorders: possible involvement of TGF-beta-induced RPE cell apoptosis Exp Eye Res 1997 65: 365–378
Gonzalez-Avila G et al. Influence on collagen metabolism of vitreous from eyes with proliferative vitreoretinopathy Ophthalmology 1995 102: 1400–1405
Hardwick C et al. Pathologic human vitreous promotes contraction by fibroblasts. Implications for proliferative vitreoretinopathy Arch Ophthalmol 1995 113: 1545–1553
Connor TB Jr et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye J Clin Invest 1989 83: 1661–1666
Shull MM et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease Nature 1992 359: 693–699
Kulkarni AB et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death Proc Natl Acad Sci USA 1993 90: 770–774
Sanford LP et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes Development 1997 124: 2659–2670
Ueno H et al. A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats Hum Gene Ther 2000 11: 33–42
Sakamoto T et al. Blockade of TGF-beta by in vivo gene transfer of a soluble TGF-beta type II receptor in the muscle inhibits corneal opacification, edema and angiogenesis Gene Therapy 2000 7: 1915–1924
Honda M et al. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration Gene Therapy 2000 7: 978–985
Shiose S et al. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma Invest Ophthalmol Vis Sci 2000 41: 2395–2403
Sakamoto T et al. Retinal functional change caused by adenoviral vector-mediated transfection of LacZ gene Hum Gene Ther 1998 9: 789–799
Sakamoto T et al. A vitrectomy improves the transfection efficiency of adenoviral vector-mediated gene transfer to Muller cells Gene Therapy 1998 5: 1088–1097
Yamamoto H et al. Adenovirus-mediated transfer of a truncated transforming growth factor-beta (TGF-beta) type II receptor completely and specifically abolishes diverse signaling by TGF-beta in vascular wall cells in primary culture J Biol Chem 1996 271: 16253–16259
Glorioso JC, Naldini L, Kay MA . Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics Nat Med 2001 7: 33–40
Liu YC, Kawagishi M, Kameda R, Ohashi H . Characterization of a fusion protein composed of the extracellular domain of c-kit and the Fc region of human IgG expressed in a baculovirus system Biochem Biophys Res Commun 1993 197: 1094–1102
Liu YC et al. Processing of a fusion protein by endoprotease in COS-1 cells for secretion of mature peptide by using a chimeric expression vector Proc Natl Acad Sci USA 1993 90: 8957–8961
Ueno H et al. Quantitative analysis of repeat adenovirus-mediated gene transfer into injured canine femoral arteries Arterioscler Thromb Vasc Biol 1995 15: 2246–2253
Tahara Y et al. The antidepressant hypericin inhibits progression of experimental proliferative vitreoretinopathy Curr Eye Res 1999 19: 323–329
Ito S et al. The effect of tranilast on experimental proliferative vitreoretinopathy Graefes Arch Clin Exp Ophthalmol 1999 237: 691–696
Fastenberg DM, Diddie KR, Dorey K, Ryan SJ . The role of cellular proliferation in an experimental model of massive periretinal proliferation Am J Ophthalmol 1982 93: 565–572
Acknowledgements
This work is supported in part by Grants-in-Aid No. 11002994 from the Scientific Research Department of the Ministry of Education, Science, Culture and Sports of the Japanese Government, the Japan Society for the Promotion of Science (Tokyo), and the Japan Eye Bank Association (Tokyo). The authors thank Dr Kenneth W Parker for editorial assistance.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oshima, Y., Sakamoto, T., Hisatomi, T. et al. Gene transfer of soluble TGF-β type II receptor inhibits experimental proliferative vitreoretinopathy. Gene Ther 9, 1214–1220 (2002). https://doi.org/10.1038/sj.gt.3301789
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301789
Keywords
This article is cited by
-
Proliferative Vitreoretinopathie-Prozess – „To heal or not to heal“
Der Ophthalmologe (2021)
-
Pharmakologische Ansätze zur Behandlung der proliferativen Vitreoretinopathie
Der Ophthalmologe (2013)
-
Prevention of radiation-induced pneumonitis by recombinant adenovirus-mediated transferring of soluble TGF-β type II receptor gene
Cancer Gene Therapy (2006)
-
Oligonucleotide-Polyethylenimine Complexes Targeting Retinal Cells: Structural Analysis and Application to Anti-TGFβ-2 Therapy
Pharmaceutical Research (2006)
-
Smad3 is required for dedifferentiation of retinal pigment epithelium following retinal detachment in mice
Laboratory Investigation (2004)